Posted On: 09/22/2016 7:42:44 PM
Post# of 72443
Their blood cancer drug failed also. If they aren't interested in B, perhaps we can introduce them to K?
Quote:
It’s not the first time Gilead has run into trial trouble. Earlier this year it halted 6 trials of its oncology med Zydelig (idelalisib) for first-line use in blood cancers after reports of serious side effects--including multiple deaths--among participants in several of the studies.
(1)
(0)
Scroll down for more posts ▼
